NuVasive Gets a Buy Rating from RBC Capital

By Ryan Adsit

RBC Capital analyst Glenn Novarro reiterated a Buy rating on NuVasive (NASDAQ: NUVA) today and set a price target of $76. The company’s shares opened today at $71.62.

According to TipRanks.com, Novarro is a top 100 analyst with an average return of 12.2% and a 82.5% success rate. Novarro covers the Healthcare sector, focusing on stocks such as Integer Holdings Corporation, Boston Scientific Corp, and Varian Medical Systems.

NuVasive has an analyst consensus of Strong Buy, with a price target consensus of $81.83.

NuVasive’s market cap is currently $3.61B and has a P/E ratio of 73.47. The company has a book value ratio of 5.2057.

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NUVA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuVasive, Inc. is medical device company, which engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.